Home›Fluticasone Propionate And Salmeterol›Fluticasone Propionate And Salmeterol + Ritonavir

Does Fluticasone Propionate And Salmeterol Interact with Ritonavir?

CDI records a contraindicated classification for Fluticasone Propionate And Salmeterol and Ritonavir. The stored summary is: Strong CYP3A4 inhibitor significantly increases fluticasone propionate exposure and reduces serum cortisol. Postmarketing reports of systemic corticosteroid effects including Cushing's syndrome and adrenal suppression. The mechanism involves cyp3a4 inhibition increases systemic corticosteroid and cardiovascular adverse effects. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Contraindicated
Ritonavir Class
Cytochrome P450 3A Inhibitor
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

CYP3A4 inhibition increases systemic corticosteroid and cardiovascular adverse effects

What To Tell Your Doctor or Pharmacist

If you are taking Fluticasone Propionate And Salmeterol and your doctor is considering prescribing Ritonavir (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Fluticasone Propionate And Salmeterol(Fluticasone Propionate And Salmeterol Diskus)+💊 Ritonavir(Norvir)

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
CDI classifies this record as contraindicated. Confirm the applicable product labeling with your prescriber or pharmacist.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
Cytochrome P450 3A Inhibitor
Source
NLP:fluticasone propionate and salmeterol

What this means in plain English

Strong CYP3A4 inhibitor significantly increases fluticasone propionate exposure and reduces serum cortisol. Postmarketing reports of systemic corticosteroid effects including Cushing's syndrome and adrenal suppression.

About Fluticasone Propionate And Salmeterol and Ritonavir

Ritonavir is a Cytochrome P450 3A Inhibitor. Ritonavir is also sold under the brand name Norvir. Ritonavir additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:fluticasone propionate and salmeterol

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Fluticasone Propionate And Salmeterol and Ritonavir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations